Sutent Adjunctive Treatment of Differentiated Thyroid Cancer
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This study is comparing a drug called Sutent with standard of care treatment for people with
advanced thyroid cancer. Because advanced thyroid cancer is becoming increasingly common and
effective treatment options are limited, new therapies are desperately needed.
This study is designed to see if Sutent following therapy with radioactive iodine will target
cancer cells and delay disease progression better than standard therapy alone. Newly
diagnosed patients, who are scheduled to receive radioactive iodine as part of their standard
care are possible candidates. By entering into this study, participants agree to take oral
Sutent for approximately two years after completing standard therapy. During this time, study
participants will be followed closely by their doctor.
Phase:
Phase 2
Details
Lead Sponsor:
Medstar Health Research Institute Washington Hospital Center